Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Fintel reports that on July 21, 2025, Needham downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Hold to ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...